<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Gideon Bollag et al.|New England Journal of Medicine|2012Cited by 1k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978